Outlook Therapeutics (OTLK) Profit After Tax: 2015-2024
Historic Profit After Tax for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to -$75.4 million.
- Outlook Therapeutics' Profit After Tax rose 1.73% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$35.2 million, marking a year-over-year decrease of 2.07%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- Latest data reveals that Outlook Therapeutics reported Profit After Tax of -$75.4 million as of FY2024, which was down 27.78% from -$59.0 million recorded in FY2023.
- Outlook Therapeutics' Profit After Tax's 5-year high stood at -$35.2 million during FY2020, with a 5-year trough of -$75.4 million in FY2024.
- Its 3-year average for Profit After Tax is -$66.8 million, with a median of -$66.1 million in 2022.
- In the last 5 years, Outlook Therapeutics' Profit After Tax plummeted by 50.86% in 2021 and then climbed by 10.70% in 2023.
- Over the past 5 years, Outlook Therapeutics' Profit After Tax (Yearly) stood at -$35.2 million in 2020, then crashed by 50.86% to -$53.2 million in 2021, then declined by 24.24% to -$66.1 million in 2022, then grew by 10.70% to -$59.0 million in 2023, then decreased by 27.78% to -$75.4 million in 2024.